{
    "2021-07-14": [
        [
            {
                "time": "",
                "original_text": "【国联医药】天坛生物：业绩优于批签发，“十四五” 发展有望超预期",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "业绩",
                        "批签发",
                        "十四五",
                        "发展"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天坛生物业绩快报：上半年净利3.39亿元 同比增20%",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "业绩快报",
                        "净利",
                        "同比增"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：2021年半年度净利润约3.39亿元，同比增加19.64%",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "半年度",
                        "净利润",
                        "同比增加"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物（600161.SH）：半年度净利升19.64%至3.39亿元",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "半年度",
                        "净利",
                        "同比上升"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：上半年净利润同比增长19.64%（业绩快报）",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "上半年",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：短期受政策扰动 关注中报高成长个股",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业周报",
                        "政策扰动",
                        "中报",
                        "高成长"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "血制品行业点评：供给放量拐点将至、浆站拓源迎机遇",
                "features": {
                    "keywords": [
                        "血制品",
                        "行业点评",
                        "供给放量",
                        "浆站",
                        "机遇"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}